drugset / Trial / NCT00601731

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

NCT00601731

Phase 2 Completed 382 enrolled Novartis Vaccines Novartis · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.

Timeline

Start
2008-02
Primary completion
2010-07
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject MenACWY-CRM197 Vaccine